Lycia Lands a $317M IPO for Inflammation Drugs Based on Nobel Prize-Winning Science
Lycia Therapeutics’ protein-degrading drugs are based on the research of Carolyn Bertozzi, a Stanford chemistry professor and Nobel laureate. Lycia’s lead drug candidate is in development for food allergy, where it could compete against the blockbuster Roche drug Xolair.
Congress’s Patient Matching Fix Won’t Work — Here’s What Would
The MATCH IT Act aims to reduce patient matching errors. But a model used by vital records systems could provide a better solution.
Physician Mental Health and Health System Privacy: Why Doctors Avoid Their Own EHR
In most organizations the default access model was built for patient care, not for protecting colleagues. A nurse on another unit, a resident who rotated with them, a department administrator: any of them may technically be able to open the record, even when policy says they should not.
Fractyl’s Weight Maintenance Device Meets Clinical Goal, but Shares Nosedive, Layoffs Follow
Fractyl Health reported positive six-month trial results from an investigation of its Revita procedure last week, but shares of Fractyl stock dropped steeply on October 16 immediately following the announcement. Despite the positive findings, the stock’s sharp decline highlighted a contrast between the clinical findings and the market’s response.
Where Are the Biggest Opportunities in Women’s Cardiovascular Health?
MedTech Conference panelists cited inflammation research, listening to women, clinical trial representation and investment as priorities for women’s cardiovascular health.